Priliximab

From Self-sufficiency
Jump to: navigation, search
Priliximab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CD4
Identifiers
CAS Number 147191-91-1
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease[1] and multiple sclerosis[2][3] but has not yet received U.S. Food and Drug Administration licencing. The patent belongs to the biotechnology company Centocor.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
"-tuxi-" (tumor/cancer immunotherapy)
"-cixi-" (cardiovascular)
"-lixi-" (immune system)
"-mexi-" (melanoma)
"-baxi-" (bacterial)


40x30px This monoclonal antibody-related article is a stub. You can help ssf by expanding it.
  1. ↑ Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S (1997). "CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study". Gut. 40 (3): 320–7. PMC 1027080 Freely accessible. PMID 9135519. 
  2. ↑ Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M (1997). "Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412". Neurology. 48 (4): 810–6. PMID 9109860. 
  3. ↑ van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr H, Polman C (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial". Neurology. 49 (2): 351–7. PMID 9270561. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Priliximab&oldid=23139"